Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Thursday announced the availability of its US Food and Drug Administration (FDA) approved Cinacalcet Tablets in the United States.
Dr. Reddy's Cinacalcet Tablets are a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets. The Sensipar brand and generic market had US sales of approximately USD312m MAT for the 12 months ending in July 2020, according to IQVIA Health.
Cinacalcet Tablets are available in 30 mg, 60 mg and 90 mg tablets in a bottle count size of 30.
Cinacalcet is a medication used to treat secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets